The premise of this review is that the developing immune system represents a particularly sensitive xenobiotic target that is not effectively modeled through routine screening for immunotoxicity using adult exposure. Hence, adult exposure testing for immunotoxicity is limited in application, cannot address the most significant immune vulnerabilities, and should be replaced with a more predictive assessment protocol. This conclusion is drawn from recent developmental immunotoxicity findings, including those from our own laboratory, as well as from the conclusions of numerous conferences and workshops. These sources point to the special vulnerabilities of the perinatal immune system compared with the fully matured and dispersed immune system of the adult.

Individuals in early-life stages have been recognized as a special subset of the population that is likely to be at greater toxicologic risk than adults ([@b19-ehp0114-000477]; [@b69-ehp0114-000477]; [@b75-ehp0114-000477]; [@b115-ehp0114-000477]). Within this broader framework, a significant number of recent review and consensus workshop reports have stressed that early-life exposure to xenobiotics poses the greatest environmental risk for the immune system and would be expected to exert the greatest effect on subsequent human health ([@b22-ehp0114-000477]; [@b23-ehp0114-000477], [@b24-ehp0114-000477]; [@b49-ehp0114-000477]; [@b52-ehp0114-000477]; [@b56-ehp0114-000477]; [@b68-ehp0114-000477]; [@b82-ehp0114-000477]; [@b86-ehp0114-000477]; [@b131-ehp0114-000477]). Yet, immune-associated safety from problematic exposure to environmental chemicals as well as drugs has hinged on adult exposure assessment \[[@b48-ehp0114-000477]; [@b87-ehp0114-000477] [@b128-ehp0114-000477]\]. Developmental immunotoxicity screening was not included in one recent immunotoxicity draft guidance covering human pharmaceuticals ([@b129-ehp0114-000477]), although its potential application within safety screening is under ongoing consideration ([@b56-ehp0114-000477]; [@b72-ehp0114-000477]).

In this review we highlight some novel processes of perinatal immune development that both contribute to the immunotoxic vulnerability of the developing immune system and cannot be effectively examined via current adult-exposure assessment. Additionally, specific examples of the problems associated with reliance on adult-induced immunotoxicity assessment are shown for a variety of immunotoxicants.

Perinatal Immune Development versus the Adult Immune System
===========================================================

Immune development has been characterized from a toxicologic perspective through a series of discrete functional changes representing critical windows of differential vulnerability to toxicants ([@b23-ehp0114-000477]; [@b57-ehp0114-000477]; [@b73-ehp0114-000477]; [@b74-ehp0114-000477]; [@b79-ehp0114-000477]). These reviews have emphasized that each "window" of development likely has different immunologic risks associated with immunotoxicant exposure, and indeed, examples of differential immunotoxic outcomes among these windows do exist ([@b8-ehp0114-000477]; [@b77-ehp0114-000477]). Although it is not practical or necessary to directly evaluate the differential risk of limited exposures over different periods within perinatal development, it is important to accurately estimate immunologic risk across the entire period of immune development because of the important role of effective immune function in children's health ([@b19-ehp0114-000477]; [@b68-ehp0114-000477]).

[Table 1](#t1-ehp0114-000477){ref-type="table"} draws upon the broader critical windows of immune development ([@b23-ehp0114-000477]) to illustrate a set of seven discrete events that are either unique to perinatal immune development or critical to the post-natal immune integrity while serving a different role in the adult. These immune events include those that are restricted solely to the immune system as well as some involving the role of the immune system in host organ/tissue homeostasis. In most cases, clear associations exist between exposure to specific toxicants and disruption of the perinatal event. It is not simply by chance that this set of early immune events seems to impinge primarily on the risk of atopy, autoimmune disease, and later-life immune balance (which also influences risk of cancer, etc.). In fact, the perinatal period of immune development is precisely the period in which immune balance must shift from that of an allogeneic yet full-term fetus to that of an offspring ready to meet the complete spectrum of disease challenges. At the heart of the issue is the fact that impact of a xenobiotic on that shift cannot be tested with adult exposure assessment.

Establishing and Renewing Macrophage-Derived Cells in Critical Tissues
======================================================================

One of the early events connecting the immune system to virtually all organs is the differentiation and seeding of myelomonocytic lineage macrophages and macrophage-derived cells to various sites, including the bronchial (e.g., alveolar macrophages), hepatic (Kupffer cells), neurologic (microglia), and reproductive systems (testicular macrophages). These cells provide regulatory and host defense roles in these tissues. Specific examples describe the vulnerability of these tissues during the perinatal period when exposure to toxicants impairs macrophages, including the possibility that the heavy metal lead can impair both the function and the self-renewal of testicular macrophages, which contributes to male sterility problems ([@b102-ehp0114-000477]). Similarly, pulmonary and alveolar macrophages play a key role in lung development ([@b4-ehp0114-000477]), and sensitivity of the perinatal lung to some environmental agents is directly related to alterations in early-life macrophage populations ([@b12-ehp0114-000477]; [@b80-ehp0114-000477]). In the brain, inappropriate cytokine production from microglial cells and/or astrocytes is now recognized as an early component of many postnatal neurologic diseases ([@b3-ehp0114-000477]; [@b10-ehp0114-000477]; [@b97-ehp0114-000477]; [@b107-ehp0114-000477]). With Kupffer cells in the liver ([@b100-ehp0114-000477]), researchers recently found that their capacity to develop a tolerance for lipopolysacharride (LPS) ([@b127-ehp0114-000477]) is critical for the ability of the liver to control inflammation.

Lymphoid seeding of the thymus and thymopoiesis.
------------------------------------------------

Another early immune process critical for subsequent host defense is the migration of pro--T lymphocytes to the thymus and their expansion during thymopoiesis. During the perinatal period, the thymus is central to the production of T lymphocytes. Even in children, the thymus continues to play the major role in T-lymphocyte generation ([@b89-ehp0114-000477]; [@b114-ehp0114-000477]). In contrast, the thymus has a much different role in the adult. Although the adult thymus retains some capacity for the production of cells, particularly with severe immune depletion, its role remains minor in the repopulation of T lymphocytes ([@b43-ehp0114-000477]; [@b104-ehp0114-000477]). Instead, most T-lymphocyte production comes from the periphery in adults ([@b43-ehp0114-000477]). The ramifications of this are that the targeting of pro--T lymphocytes by chemicals or drugs and/or induction of thymus atrophy would be expected to have different consequences depending upon age. As shown in [Table 1](#t1-ehp0114-000477){ref-type="table"}, several environmental agents appear to target either pro--T lymphocytes or the thymopoiesis process.

Negative selection in the thymus of auto-reactive T-cell clones.
----------------------------------------------------------------

A third early immune process critical for host integrity is the negative selection and removal of autoreactive T-lymphocyte clones in the thymus. This occurs during the process sometimes designated as "T-cell education." [@b98-ehp0114-000477] provided a clear demonstration of this process as it occurs in humans. Partially mature thymocytes undergo negative selection at the corticomedullary boundary and in the medulla of thymus ([@b123-ehp0114-000477]). This process is essential if self-reactive clones are to be eliminated before birth. Conversely, excessive loss of thymocytes during negative selection leads to T-cell depletion. Although explicit examples of chemicals or drugs blocking negative selection have yet to be determined, this perinatally unique stage of immune development would appear to be a significant factor in later-life autoimmune disease. Metals represent one category of immunotoxicants warranting examination based on the capacity of mercury and other metals to either trigger or accelerate the progression of autoimmune manifestations ([@b31-ehp0114-000477]; [@b76-ehp0114-000477]; [@b111-ehp0114-000477]). Conversely, some chemicals are known to disrupt the negative selection process by overpromoting negative selection and inappropriate thymocyte apoptosis. 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD) is an example of such a toxicant ([@b11-ehp0114-000477]; [@b30-ehp0114-000477]).

Thymic Generation of Regulatory T-Cells (CD4^+^CD25^+^ High Expression) and Acquisition of Tolerance
====================================================================================================

A parallel protection against self-reactivity resides in the gestational thymic production and subsequent activation of a specialized population of regulatory T lymphocytes. The specialized regulatory T-cell (Treg) population carries the phenotype FoxP3^+^CD4^+^CD25^+^ and develops during gestation (\~ 12--13 weeks) in the human fetus ([@b17-ehp0114-000477]; [@b18-ehp0114-000477]). Tregs are critical in the suppression of autoreactive lymphocytes that have escaped elimination through negative selection in the thymus ([@b17-ehp0114-000477]; [@b70-ehp0114-000477]; [@b112-ehp0114-000477]). It appears that Tregs acquire their regulatory and suppressive phenotype while within the fetal thymus and are further activated in peripheral lymphoid organs ([@b17-ehp0114-000477]). The process through which these cells emerge and acquire the capacity to identify and suppress self-reactive lymphoid clones occurs embryonically. As with negative selection discussed previously, the active perinatal process of producing and activating Tregs is a logical stage where toxicant-induced risk of later-life autoimmune disease would be great. Evidence suggests that some doses of cyclophosphamide ([@b88-ehp0114-000477]) and cyclosporin A ([@b67-ehp0114-000477]) cause inhibition of Treg populations. Treg suppression is thought to be one route to increase allergic disease ([@b109-ehp0114-000477]), and the breaking of tolerance to nickel has been associated with Treg suppression ([@b13-ehp0114-000477]).

Maturation of dendritic cells from the fetal (immature) phenotype.
------------------------------------------------------------------

Dendritic cells are known to be important in antigen presentation and in determining the nature of subsequent immune responses. A fifth perinatal process involves the maturation of immature dendritic cells to produce interleukin (IL-12) (counterbalancing IL-10 production) and acquire the capability of promoting T-helper 1 (T~H~1) or type 1 responses. This does not happen in humans until parturition under normal circumstances ([@b58-ehp0114-000477]; [@b59-ehp0114-000477]).

In fact, the T~H~1 response must be suppressed until after birth to protect the pregnancy from T~H~1-mediated immunologic rejection ([@b81-ehp0114-000477]). One of the processes for accomplishing this is the metabolism of the amino acid tryptophan by the enzyme indoleamine-2,3-dioxygenase (IDO) to produce tryptophan metabolites such as kynurenines ([@b28-ehp0114-000477]; [@b42-ehp0114-000477]; [@b94-ehp0114-000477]; [@b95-ehp0114-000477]). These metabolites selectively suppress T~H~1 function by inducing apoptosis in T~H~1 but not T~H~2 cells ([@b28-ehp0114-000477]), thereby skewing responses toward T~H~2. In the fetus, this is required to avoid allogeneically induced miscarriage ([@b95-ehp0114-000477]). But in the newborn this must be corrected to provide adequate immune balance. Not surprisingly, imbalances in IDO activity have been associated with diseases such as colitis ([@b41-ehp0114-000477]) and inflammatory bowel disease ([@b136-ehp0114-000477]).

The perinatal system is exquisitely sensitive to these time/life-stage--dependent shifts in immune balance. For example, [@b92-ehp0114-000477] demonstrated that even the mode of birth delivery can influence the acquisition of T~H~1 cytokine production capacity in humans. Newborns delivered by cesarean section remained more T~H~2 skewed compared with vaginally delivered newborns. This emphasizes the potential problems in using an adult exposure assessment protocol for immunotoxicity to model the perinatal immune changes surrounding birth.

In keeping with this idea, a recent study demonstrated that human cord blood--derived dendritic cells respond completely differently than their adult counterparts when exposed to dexamethasone ([@b91-ehp0114-000477]). Dexamethasone exposure of these immature cells prevents their maturation to promote T~H~1 responses and locks in the T~H~2 IgE-promoting phenotype. The T~H~2 skewing effect appears to be long-lasting ([@b90-ehp0114-000477]). This type of early-life-stage--restricted immunotoxicity appears to contribute to an increased risk of atopy and asthma. [@b1-ehp0114-000477] showed that maturation of newborn immature dendritic cells with LPS reduced the development of a T~H~2-associated birch allergen response. In contrast, the lack of dendritic cell maturation from the fetal immature stage was associated with children at risk for type 1 diabetes ([@b119-ehp0114-000477]). In addition to dexamethasone ([@b91-ehp0114-000477]), nicotine ([@b101-ehp0114-000477]) has been reported to block dendritic cell maturation. Again, such toxicant-induced perinatal alterations cannot be examined with adult-only exposure because extensive dendritic cell maturation would have occurred after birth and before adult exposure to the test xenobiotic.

Shifting T~H~ balance for later life.
-------------------------------------

Beyond dendritic cells, some xenobiotics such as the heavy metals and tryptophan metabolites may directly affect T~H~ cells and contribute to skewed immune responses in later life. Because mammals are born with a T~H~2-skewed functional capacity ([@b105-ehp0114-000477]), perinatal versus adult exposure assessment actually measures two different alterations. In the perinatal case, the issue is whether a xenobiotic locks in the already existing T~H~2 bias among T lymphocytes, thereby preventing the genetically influenced adult balance to be achieved postnatally. This would allow as the default an increased risk of neonatal T~H~2-associated diseases ([@b59-ehp0114-000477]). In contrast, under the best circumstances adult exposure assessment could measure only whether a xenobiotic selectively impaired T~H~1 cells in an already balanced system. At physiologic levels of exposure, many more environmental factors may be capable of delaying or reducing the efficiency of perinatal T~H~1 maturation (thereby perpetuating the fetal imbalance) than can clinically alter adult T~H~ balance.

Surfactant modulation of macrophages.
-------------------------------------

Beyond the gestational seeding of macrophages to different tissues and initial maturation *in situ*, there is a special perinatal maturation of macrophages (particularly alveolar) that enables them to acquire increasing host defense capabilities (phagocytosis, chemotaxis, tumor necrosis factor-α production, antibody-dependent cellular cytotoxicity) with increased postnatal age ([@b39-ehp0114-000477]). Hence, perinatal exposure to chemicals and drugs would target functionally immature cells in a manner unlike the fully functional population in exposed adults. Among the critical factors in this perinatal macrophage maturation is exposure to various factors known as "collectins" (surfactant proteins).

Although collectins can be immunomodulatory for adult alveolar macrophages ([@b47-ehp0114-000477]), they seem to provide important maturational signals for perinatal macrophages that go well beyond defense of the lung ([@b96-ehp0114-000477]). [@b103-ehp0114-000477] discussed the role of surfactant protein D in enhancing macrophage clearance of DNA and in minimizing anti-DNA antibody production. Additionally, [@b6-ehp0114-000477] demonstrated that surfactant interactions with macrophages and dendritic cells help to shift responses from purely innate to acquired immune responses. Surfactant protein A signals amniotic fluid macrophages to migrate to the uterus and initiate the parturition process ([@b15-ehp0114-000477]; [@b96-ehp0114-000477]). Complicating the age issue is the fact that surfactant content varies with age ([@b26-ehp0114-000477]). Obviously, such perinatal alterations in macrophage activities are difficult to evaluate using adult-only exposure to potential immunotoxicants.

Although these developmental immune events illustrate the biological problem with modeling immunotoxicologic risk using adult exposures, the resulting underestimation of perinatal sensitivity can take several forms. These are described in the following section.

Nature of Increased Perinatal Immunotoxic Sensitivity
=====================================================

Dose sensitivity.
-----------------

The increased sensitivity of the developing versus the adult immune system to immunotoxic alteration can take several forms. First, early-life stages have increased dose sensitivity to most toxicants. There are several examples suggesting that the developing immune system is altered by significantly lower doses of toxicants than those required to produce effects in the adult. Such comparisons were recently reviewed in [@b82-ehp0114-000477]. Lead ([@b14-ehp0114-000477]; [@b46-ehp0114-000477]; [@b93-ehp0114-000477]; [@b99-ehp0114-000477]; [@b122-ehp0114-000477]) appears to differ across ages for immunotoxic end points ranging from 3- to 12-fold in lowest observed adverse effect levels (LOAELS). Similarly, mercury appears to have age-based differences ([@b45-ehp0114-000477]; [@b60-ehp0114-000477]; [@b118-ehp0114-000477]). With TCDD the age-based range in LOAELS appears to be even greater ([@b34-ehp0114-000477], [@b35-ehp0114-000477]; [@b33-ehp0114-000477]; [@b121-ehp0114-000477]; [@b134-ehp0114-000477]; see also [Table 2](#t2-ehp0114-000477){ref-type="table"}).

Range and severity of effects.
------------------------------

A second measure of differential age-based sensitivity to immunotoxicants concerns the spectrum and severity of effects. Not surprisingly, immunotoxicants frequently produce a different and unpredictable array of alterations when the exposure occurs *in utero* or in the early neonate versus the adult. Among those immunotoxicants that produce different ranges or severities of outcomes depending upon age of exposure are lead ([@b8-ehp0114-000477]; [@b77-ehp0114-000477]), methoxychlor ([@b135-ehp0114-000477]), T-2 toxin ([@b51-ehp0114-000477]), benzo\[*a*\]pyrene ([@b53-ehp0114-000477]; [@b110-ehp0114-000477]), chlordane ([@b2-ehp0114-000477]), 7,12-dimethylbenz\[*a*\]anthracene ([@b16-ehp0114-000477]; [@b53-ehp0114-000477]; [@b55-ehp0114-000477]), ethanol ([@b37-ehp0114-000477], [@b38-ehp0114-000477]; [@b36-ehp0114-000477]), nonylphenol ([@b66-ehp0114-000477]), tributyltins ([@b120-ehp0114-000477]; [@b126-ehp0114-000477]; [@b133-ehp0114-000477]), and genistein ([@b40-ehp0114-000477]).

For example, with methoxychlor exposure of rats, F~1~ males had significantly elevated levels of splenic antibody-forming cells, unlike their exposed mothers, whereas F~1~ females had a significantly reduced percentage of CD8^+^ T cells (at all doses examined) with no corresponding effect in the exposed dams ([@b135-ehp0114-000477]). Likewise with genistein exposure, exposed F~0~ rat dams displayed altered natural killer (NK) activity, whereas their daughters exposed *in utero* had altered antibody-forming cell activity but no change in NK activity ([@b40-ehp0114-000477]). With TCDD exposure in rats to assess persistent effects, exposed offspring had a significant reduction in contact hypersensitivity with no effect in the exposed dams ([@b134-ehp0114-000477]). These examples illustrate that adult exposure assessment is inherently ineffective in predicting the range of likely immunotoxic effects after *in utero* exposure.

Persistence of effects.
-----------------------

Another feature of developmental immunotoxicity is that alterations after early exposure are frequently persistent and last long after exposure, frequently into adulthood of the exposed offspring. Examples where early xenobiotic exposure results in a greater persistence of effects than would be predicted from adult exposure assessment are found with diethylstilbestrol (DES) ([@b29-ehp0114-000477]; [@b50-ehp0114-000477]; [@b64-ehp0114-000477]; [@b85-ehp0114-000477], [@b84-ehp0114-000477]) and cyclosporin A ([@b62-ehp0114-000477]).

Latency.
--------

Finally, one of the anomalies of early exposure is that a sublethal exposure to a toxicant may produce an unrecognizable immunotoxic alteration until the postnatal immune system is placed under subsequent stress. This hidden or cryptic state is referred to as "latency." A classic example exists for early exposure to DES ([@b29-ehp0114-000477]). In this case, an apparently innocuous early exposure to DES alters the immune system in such a manner that it responds to a second adult estrogenic exposure (which of itself has no effect) with a completely aberrant cytokine production profile. The *in utero* exposure to DES primes the immune system for postnatal unpredictable responses. A similar example has been seen after low-level exposure to lead where postnatal viral infection resulted in unpredictable alterations in leukocyte mobilization ([@b78-ehp0114-000477]). Obviously, adult exposure assessment affords no opportunity to examine this phenomenon of embryonic-induced immune latency.

Sex Differences in Sensitivity Outcome
======================================

Differential immunotoxic effects between sexes are neither universal after early exposure ([@b132-ehp0114-000477]) nor unique to early-life stages. However, a surprising number of examples exist in which males and females have different immune outcomes after perinatal xenobiotic exposure. Xenobiotics can have different effects on the developing immune system based on the hormonal environment ([@b61-ehp0114-000477]). Among the chemicals listed in [Table 2](#t2-ehp0114-000477){ref-type="table"}, gender differences in developmental immunotoxicity have been reported for lead ([@b7-ehp0114-000477], [@b8-ehp0114-000477], [@b9-ehp0114-000477]; [@b99-ehp0114-000477]), mercury ([@b118-ehp0114-000477]), genistein ([@b40-ehp0114-000477]), nonylphenol ([@b66-ehp0114-000477]), TCDD ([@b35-ehp0114-000477]), and methoxychlor ([@b135-ehp0114-000477]).

Need for Nonadult Exposure Assessment
=====================================

[Table 2](#t2-ehp0114-000477){ref-type="table"} lists examples of immunotoxicants where age-based comparisons exist and adult exposure assessment is not predictive of perinatal sensitivity to the xenobiotic. Although basic hazard identification could be performed on most of the toxicants listed using only adult exposure data, there would be little guidance for protecting early life stages from problematic exposure of the developing immune system. This is one reason that several recent reviews have suggested the benefit of exposure regimes that include all nonadult (conception, gestation, lactation, juvenile) stages of development ([@b57-ehp0114-000477]; [@b68-ehp0114-000477]; [@b86-ehp0114-000477]). Recent findings of key maturation events surrounding birth and of chemical- and drug-induced disruption of those immune-associated events ([@b91-ehp0114-000477]; [@b90-ehp0114-000477]; [@b117-ehp0114-000477]) are further indications that adult-only exposure protocols are unlikely to accurately predict the risk of perinatal immunotoxicity. Exposure over the nonadult stages of immune development is more likely to include those age-based populations at greatest risk.

Conclusions
===========

Many critical processes occurring during peri-natal immune development are either nonexistent or comparatively unimportant in the adult (e.g., [Table 1](#t1-ehp0114-000477){ref-type="table"}). Therefore, when safety limits are established on the basis of adult immune exposure data, they likely have limited use for predicting developmental immunotoxicity and protection of the nonadult. For the chemicals and drugs compared across age groups to date, the developing immune system has a greater sensitivity than that of the fully matured adult. Because this increased sensitivity can take different forms (e.g., [Table 2](#t2-ehp0114-000477){ref-type="table"}), use of magnitude safety factors is of limited benefit in the absence of relevant exposure data. Where adult exposure protocols are used as the only yardstick of immunotoxic safety, consideration should be given to replacing these protocols with exposure regimes extending throughout the nonadult period of development. Given the specific pattern of perinatal immune alterations, it is likely that they explain, in part, the increased incidence of such human diseases as atopy, asthma, and certain autoimmune manifestations.

Support of the authors for research on this topic, including partial salary recovery, was provided by grants or contracts from the National Institute of Environmental Health Sciences \[Superfund Basic Research and Education Program via the U.S. Environmental Protection Agency (EPA)\], the American Chemistry Council (ACC), the U.S. EPA, and the U.S. Department of Agriculture (USDA).

The ACC and the USDA provided salary support for M.S.P. Research support for R.R.D. during the past 5 years has been from the ACC and the USDA (Developmental Immunotoxicology) and from the USDA and New York State (Environment and Breast Cancer).

###### 

Immune toxicant targets associated with perinatal development.

  Key perinatal immune events                                                                                        Timing in humans                                               Benefit to host                                                                                                                                        Examples of concern                                                                                Health ramifications                                                                                                                                               Key references
  ------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Differentiation and seeding of macrophages to tissues                                                              6--24 WG                                                       Self-renewing populations of microglia, Kupffer cells, and alveolar macrophages; resident macrophage functioning in tissues (e.g., testis)             Lead, LPS, ozone, cyclophosphamide                                                                 Inflammation of lung, brain, or liver tissue dysfunction (e.g., male infertility)                                                                                  [@b12-ehp0114-000477]; [@b44-ehp0114-000477]; [@b63-ehp0114-000477]; [@b102-ehp0114-000477]
  Seeding of thymus by pro--T cells and thymopoiesis to expand populations                                           Seeding 8--12 WG, massive expansion of populations 14--26 WG   Production of T-cell clones necessary to establish peripheral T-lymphocyte populations                                                                 PAHs, T-2 toxin, tributyltins, TCDD                                                                Thymic atrophy, decreased postnatal T cells and T-dependent function, increased risk of cancer and infectious diseases                                             [@b34-ehp0114-000477]; [@b53-ehp0114-000477], [@b54-ehp0114-000477]; [@b51-ehp0114-000477], [@b55-ehp0114-000477]; [@b120-ehp0114-000477], [@b121-ehp0114-000477]; [@b133-ehp0114-000477]; [@b134-ehp0114-000477]
  Negative selection and apoptosis of autoreactive thymocytes                                                        15--26 WG                                                      Elimination of most peripheral T-lymphocyte clones                                                                                                     TCDD promotes unnecessary negative thymocyte selection increasing apoptotic cell death             If promoted, then deceased numbers of thymocytes. If impaired, then, increased risk of later-life self- reactivity                                                 [@b11-ehp0114-000477]; [@b30-ehp0114-000477]
  Treg cell (CD4^+^CD25^+^ high) population generation in thymus, seeding and activation in periphery                Thymus appearance 12--13 WG; periphery 14--16 WG               Active suppression of postnatal autoreactive T-cell clones                                                                                             Possible low-dose cyclophosphamide, selected doses of cyclosporin A                                If excessively promoted, then possible immune suppression. If impaired, then increased risk of later autoimmunity or allergy (e.g. breaking tolerance to nickel)   [@b13-ehp0114-000477]; [@b17-ehp0114-000477]; [@b18-ehp0114-000477]; [@b67-ehp0114-000477]; [@b88-ehp0114-000477]; [@b109-ehp0114-000477]; [@b130-ehp0114-000477]
  Perinatal dendritic cell maturation to support T~H~1 responses                                                     Birth--juvenile                                                Increase in dendritic cell maturation and T~H~1-promoting capacity after birth to achieve necessary T~H~1 balance                                      Dexamethasone, nicotine                                                                            Increased risk of allergy and some forms of autoimmunity (e.g., type 1 diabetes)                                                                                   [@b1-ehp0114-000477]; [@b21-ehp0114-000477]; [@b71-ehp0114-000477], [@b91-ehp0114-000477]; [@b101-ehp0114-000477]; [@b108-ehp0114-000477]; [@b119-ehp0114-000477]
  Increase in T~H~1 response capacity among peripheral T lymphocytes after birth                                     Birth--juvenile                                                Needed to avoid life-long T~H~2 skewing                                                                                                                Lead, mercury, kynurenines selectively impair T~H~1 cells, 1-methyl-tryptophan may promote T~H~1   With depressed T~H~1, increased risk of T~H~2 associated diseases such as atopy and asthma                                                                         [@b8-ehp0114-000477], [@b9-ehp0114-000477]; [@b28-ehp0114-000477]; [@b95-ehp0114-000477]; [@b99-ehp0114-000477]; [@b118-ehp0114-000477]; [@b122-ehp0114-000477]
  Maturation and regulation of fetal macrophages via interactions with surfactants A and D and glutathione sources   16 WG neonatal period SP-D; 19 WG neonatal period SP-A         Needed to avoid oxidative damage to lung and increased risk of respiratory disease; needed to facilitate parturition, needed to regulate macrophages   Ethanol                                                                                            Increased risk of childhood respiratory disease; potential problems with labor, increased risk of autoimmune disease                                               [@b32-ehp0114-000477]; [@b65-ehp0114-000477]; [@b103-ehp0114-000477]; [@b106-ehp0114-000477]; [@b116-ehp0114-000477]; [@b138-ehp0114-000477]

Abbreviations: LPS, lipopolysaccharide; PAHs, polycyclic aromatic hydrocarbons; SP-A, surfactant protein A; SP-D, surfactant protein D; T, thymic derived; TCDD, 2,3,7,8-tetra-chlorodibenzo-*p*-dioxin; T~H~1, T helper 1; T~H~2, T helper 2; Treg, T regulatory; WG, weeks of gestation.

###### 

Examples of perinatal-induced immune outcomes not predicted by standard adult-exposure assessment.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Chemical/drug                       Nature of age-based difference                               Reference(s)
  ----------------------------------- ------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Benzo\[*a*\]pyrene                  Severity of effects (e.g., impact of fetalthymic atrophy)    [@b53-ehp0114-000477]; [@b83-ehp0114-000477]; [@b110-ehp0114-000477]; [@b137-ehp0114-000477]

  Chlordane                           Dose sensitivity, spectrum of effects                        [@b2-ehp0114-000477]; [@b5-ehp0114-000477]; [@b124-ehp0114-000477]; [@b125-ehp0114-000477]

  Cyclosporin A                       Persistence of effects                                       [@b62-ehp0114-000477]

  Dexamethasone                       Dose sensitivity\                                            [@b25-ehp0114-000477]; [@b91-ehp0114-000477]
                                      Spectrum of effects                                          

  Diazepam                            Dose sensitivity\                                            [@b20-ehp0114-000477]; [@b113-ehp0114-000477]
                                      Spectrum/severity of effects                                 

  DES                                 Persistence of effects\                                      [@b29-ehp0114-000477]; [@b64-ehp0114-000477]; [@b84-ehp0114-000477]
                                      Latency                                                      

  7,12-Dimethybenz\[*a*\]anthracene   Severity of effects (e.g., impact of fetal thymic atrophy)   [@b54-ehp0114-000477]

  Ethanol                             Latency, different developmental window effects              [@b37-ehp0114-000477], [@b38-ehp0114-000477]; [@b36-ehp0114-000477]

  Genistein                           Different spectrum of effects                                [@b40-ehp0114-000477]

  Lead                                Dose sensitivity\                                            [@b7-ehp0114-000477], [@b8-ehp0114-000477], [@b9-ehp0114-000477], [@b14-ehp0114-000477]; [@b27-ehp0114-000477]; [@b46-ehp0114-000477]; [@b77-ehp0114-000477], [@b78-ehp0114-000477]; [@b93-ehp0114-000477]; [@b99-ehp0114-000477]; [@b122-ehp0114-000477]
                                      Differences in spectrum of effects\                          
                                      Latency                                                      

  Methoxychlor                        Spectrum/severity of effects                                 [@b135-ehp0114-000477]

  Mercury                             Dose sensitivity                                             [@b45-ehp0114-000477]; [@b60-ehp0114-000477]; [@b118-ehp0114-000477]

  Nonylphenol                         Spectrum/severity of effects                                 [@b66-ehp0114-000477]

  Paracetamol                         Dose sensitivity                                             [@b117-ehp0114-000477]

  T-2 toxin                           Severity of effects (e.g., impact of fetal thymic atrophy)   [@b16-ehp0114-000477]; [@b51-ehp0114-000477]; [@b55-ehp0114-000477]

  TCDD                                Dose sensitivity                                             [@b34-ehp0114-000477], [@b35-ehp0114-000477]; [@b33-ehp0114-000477]; [@b121-ehp0114-000477]; [@b134-ehp0114-000477]

  Tributyltins                        Dose sensitivity\                                            [@b126-ehp0114-000477]; [@b133-ehp0114-000477];\
                                      Spectrum/severity of effects                                 [@b120-ehp0114-000477]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
